- Research works
- 0 fractional, all time
- Citations
- 31 62.0 per fractional work
- Top-10% rate
- 100.0% record average 16.5%
- Open access
- 100% world 28%
Not ranked overall: EpiPharm (Switzerland) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does EpiPharm (Switzerland) publish most on?
By volume: Lung Cancer Diagnosis and Treatment, Economic and Financial Impacts of Cancer and Health Systems, Economic Evaluations, Quality of Life.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works
- 2 Economic and Financial Impacts of Cancer Economics and Econometrics 0 works
- 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
Other research institutions in Binningen
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.